Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Venglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG known ✓ | Q16739 | 1/20 | 0.83 |
| ▸ | NTMT1 | Q9BV86 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Venglustat SCHEMBL31522597 | 1.00 | NTMT1 (0.83) | NTMT1UGCG | |
| Venglustat SCHEMBL12615333 | 0.91 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL29359568 | 0.91 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL12615329 | 0.91 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL19844439 | 0.91 | NTMT1 (1.00) | NTMT1UGCG | |
| SCHEMBL19407265 | 0.84 | NTMT1 (1.00) | NTMT1UGCG | |
| SCHEMBL18309554 | 0.83 | NTMT1 (1.00) | NTMT1UGCG | |
| Malic Acid SCHEMBL23234120 | 0.81 | NTMT1 (0.50) | NTMT1UGCG | |
| Malic Acid SCHEMBL17504472 | 0.80 | NTMT1 (0.52) | NTMT1UGCG | |
| Malic Acid SCHEMBL17504470 | 0.80 | NTMT1 (0.52) | NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626424-A1 | VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4 | GENZYME CORPORATION (US) | 2025-10-08 | — | — | EP | claimed |
| WO-2024116127-A1 | VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4 | GENZYME CORPORATION (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4349408-A2 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2024-04-10 | — | — | EP | claimed |
| US-20240091208-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | GENZYME CORPORATION | 2024-03-21 | — | — | US | claimed |
| US-11857512-B2 | Pharmaceutical compositions comprising venglustat | GENZYME CORPORATION (US) | 2024-01-02 | — | — | US | claimed |
| EP-4185267-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | Genzyme Corporation (US) | 2023-05-31 | — | — | EP | claimed |
| US-20220023272-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | GENZYME CORPORATION | 2022-01-27 | — | — | US | claimed |
| WO-2022018695-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | GENZYME CORPORATION (US) | 2022-01-27 | — | — | WO | claimed |
| WO-2025262570-A1 | VENGLUSTAT AS AN INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE IN SUBJECTS HAVING HEPATIC IMPAIRMENT | GENZYME CORPORATION (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250354999-A1 | BIOMARKERS OF LYSOSOMAL STORAGE DISEASE | GENZYME CORP (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4626424-A1 | VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4 | GENZYME CORPORATION (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4558828-A1 | BIOMARKERS OF LYSOSOMAL STORAGE DISEASE | GENZYME CORPORATION (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119630967-A | Biomarkers for lysosomal storage diseases | 建新公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024116127-A1 | VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4 | GENZYME CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4185267-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | Genzyme Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230067811-A1 | MODULATING LYMPHATIC VESSELS IN NEUROLOGICAL DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-03-02 | — | — | US | disclosed |
| EP-4093426-A1 | MODULATING LYMPHATIC VESSELS IN NEUROLOGICAL DISEASE | University of Virginia Patent Foundation (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220023272-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | GENZYME CORPORATION | 2022-01-27 | — | — | US | disclosed |
| WO-2022018695-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | GENZYME CORPORATION (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023272-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | SOST, SLC5A1, SLC10A6 | UGCG 60/4885NTMT1 649/4885 |
| US-20240091208-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VENGLUSTAT | SOST, SLC5A1, SLC10A6 | UGCG 60/4885NTMT1 649/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | UGCG 1842/4885NTMT1 3179/4885 |
| US-11857512-B2 | Pharmaceutical compositions comprising venglustat | SOST, SLC5A1, SLC10A6 | UGCG 60/4885NTMT1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.